Revelation Biosciences Q3 2024 GAAP EPS $(0.84) Beats $(2.84) Estimate
Revelation Biosciences +17.10%
Revelation Biosciences REVB | 0.35 | +17.10% |
Revelation Biosciences (NASDAQ:
REVB) reported quarterly losses of $(0.84) per share which beat the analyst consensus estimate of $(2.84) by 70.42 percent.